Women’s health remains significantly underfunded, under-researched, and underserved. Only 2% of global medical funding goes to research on women-specific issues. Similarly, all-female founder teams in the UK secured just 2% of total equity investment last year, down from 2.5% in 2023. Despite these challenges, Hormona is establishing a new standard for female-led healthcare innovation. By addressing the gender data gap in research and improving access to hormonal health solutions, Hormona is transforming an industry that has historically overlooked half of the population.
The health-tech company, which uses AI and at-home testing to help women track, understand, and optimise their hormones, has secured a $6.7M seed round led by Voima Ventures and co-led by SuperNode Global VC. DLF Ventures and existing investors, Nascent Invest and Techstars, also participated in the round. This investment brings Hormona’s total funding to over $11 million.
Inka Mero (Voima Ventures), an experienced health-tech and mission-driven startup investor, and Gina King (SuperNode), a founding member of the female executive network Chief, will join Hormona’s all-female board to guide its next growth phase.
The funding will accelerate Hormona’s expansion, launch its innovative hormone tests, and develop B2B partnerships while strengthening its infrastructure, marketing, and sales capabilities. The investment will also support team growth to enhance customer experience, furthering Hormona’s mission to redefine hormone health globally.
Behind Hormona: When personal pain sparked global change
Founded in London in 2020 by Karolina Löfqvist (CEO) and Jasmine Tagesson (COO), Hormona emerged from Karolina’s struggle with undiagnosed hormonal health issues — a common experience, as 80% of women face hormone-related problems globally.
Karolina Löfqvist brings expertise from management consulting at Valcon and financial services at Fisher Investments, along with recognition as Entrepreneur of the Year (2007) for her e-commerce ventures. Jasmine Tagesson, as COO, contributes her Creative Director background and expertise in user experience and product development. The platform combines scientific rigour with user-friendly design, developed in collaboration with clinical experts in endocrinology, gynaecology, and nutrition.
Hormona CEO and Co-founder Karolina Löfqvist comments: “For too long, women have suffered through hormonal issues, relying on trial and error and waiting until symptoms become unbearable. That’s no way to live. We built Hormona to change that—to give women control over their hormonal health without having to spend years suffering, as I did. This investment brings us one step closer to making real-time hormone tracking accessible to women everywhere without the need for multiple blood draws. We’re proud to lead and improve women’s health, one user at a time.”
Over four years, Hormona has developed groundbreaking, fully quantitative hormone tests that cover the complete clinical spectrum. Achieving over 90% accuracy compared to traditional venous blood sampling, the company’s proprietary at-home urine testing system measures three key hormones in under 15 minutes, eliminating the need for laboratory visits.
The company’s educational app has reached users in over 190 countries, showing 30% month-over-month growth with 80% user retention after 12 months. Hormona has built a strong brand and global community, garnering over 100 million views on Instagram and exceeding 5 million likes on TikTok — clear evidence of the high demand for hormonal health education and support.
Reinventing hormone testing, removing the need for a lab
Unlike period trackers (e.g., Clue, Flo Health) or fertility-focused apps (e.g., Natural Cycles), Hormona addresses the complete spectrum of hormonal health. It’s a fully quantitative at-home test that analyses multiple hormones, surpassing competitors’ qualitative or single-hormone tests.
Unlike alternatives that only track symptoms or provide retrospective insights, the platform’s AI-driven, longitudinal analysis enables proactive health management. Hormona distinguishes itself through its comprehensive approach to education, community building, and B2B partnerships. Additional features include cycle-specific lifestyle guidance, symptom management plans, and supplements. Partners can receive phase-specific email updates with support tips.
Combining AI-driven insights with innovative at-home testing, Hormona tracks hormonal fluctuations and detects imbalances. This unique integration of technology and scientific testing makes it a pioneer in digital health, helping users understand conditions like PCOS, irregular cycles, and perimenopause while normalising routine hormone testing.
Hormona’s innovative technology provides continuous, affordable hormone tracking rather than one-off tests. Its AI platform analyses long-term hormone patterns, delivering personalised insights and recommendations based on individual data. This approach helps women manage their health proactively instead of merely reacting to symptoms.
While traditional hormone tests cost approximately $174/£149 per test, Hormona offers affordable, ongoing tracking without laboratory visits. No other market solution provides such comprehensive hormone pattern analysis, leaving millions without complete hormonal health insights. This gap contributes to broader gender health disparities, with women spending 25% more of their lives in poor health than men.
Inka Mero, Managing Partner and Founder at Voima Ventures, adds: “At Voima Ventures, we seek out visionary teams and bold science that can redefine entire industries, and Hormona is exactly that: they are pioneering a global movement in women’s health. By tackling one of the most overlooked yet fundamental aspects of women’s well-being – hormonal health – they are giving millions of women the tools, data, and empowerment to take control of their bodies and lives. We are incredibly proud to stand beside Hormona as they lead this health revolution.”
Gina King, Partner at SuperNode Global VC, comments: “The future of women’s health is proactive, data-driven, and deeply personalised – and Hormona is making that a reality. They’re bringing cutting-edge innovation to an area long overlooked by investment and technology, turning hormone health from guesswork into precision. At Supernode Global, we invest in companies that empower people in how they live, and Hormona exemplifies that mission. By providing women with insights that were once out of reach, Hormona is transforming the healthcare landscape. They represent the world-changing platform we’re proud to support as they scale globally and help millions of women live to their fullest potential.”
Hormona aims to become the global standard for hormone health, making regular monitoring routine as checking blood pressure or glucose levels. Through closing the gender health gap and empowering women with data, the company seeks to improve health outcomes for millions worldwide while driving innovation in women’s health.
